Douglas Linn is a Principal Scientist at Merck, where they lead research initiatives since 2022. Previously, they served as an Associate Principal Scientist and Senior Scientist in In Vivo Pharmacology at Merck from 2014 to 2017, focusing on immuno-oncology and preclinical models. Douglas completed a postdoctoral fellowship at Brigham and Women's Hospital, investigating prostate cancer mechanisms from 2011 to 2014, and earned a Ph.D. in Pharmacology and Toxicology from the University of Maryland Baltimore. Their early research experience includes a role as a Research Assistant at New River Pharmaceuticals, where they developed prodrug conjugates.
This person is not in the org chart
This person is not in any teams
This person is not in any offices